Advertisement


Related Videos

Amit Sanyal, MD: A Clinician’s Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Advertisement

Advertisement




Advertisement